-$0.67 EPS Expected for Proteostasis Therapeutics Inc (PTI) This Quarter

Analysts expect Proteostasis Therapeutics Inc (NASDAQ:PTI) to post ($0.67) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Proteostasis Therapeutics’ earnings. The highest EPS estimate is ($0.61) and the lowest is ($0.72). Proteostasis Therapeutics posted earnings per share of ($0.38) during the same quarter last year, which would indicate a negative year-over-year growth rate of 76.3%. The company is scheduled to announce its next earnings results on Thursday, March 29th.

According to Zacks, analysts expect that Proteostasis Therapeutics will report full-year earnings of ($2.50) per share for the current fiscal year, with EPS estimates ranging from ($2.56) to ($2.44). For the next financial year, analysts forecast that the firm will report earnings of ($2.36) per share, with EPS estimates ranging from ($2.82) to ($1.89). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that cover Proteostasis Therapeutics.

Proteostasis Therapeutics (NASDAQ:PTI) last posted its quarterly earnings data on Tuesday, November 14th. The company reported ($0.56) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.72) by $0.16. Proteostasis Therapeutics had a negative net margin of 712.49% and a negative return on equity of 93.15%. The company had revenue of $1.55 million during the quarter, compared to analyst estimates of $1.38 million.

PTI has been the subject of several recent analyst reports. Zacks Investment Research cut shares of Proteostasis Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 18th. Robert W. Baird raised their target price on shares of Proteostasis Therapeutics from $13.00 to $25.00 and gave the stock an “outperform” rating in a report on Tuesday, December 12th. Leerink Swann raised their target price on shares of Proteostasis Therapeutics from $6.00 to $8.00 in a report on Tuesday, December 12th. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Proteostasis Therapeutics in a report on Tuesday, December 19th. Finally, ValuEngine cut shares of Proteostasis Therapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. Two research analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $16.00.

In related news, Director Franklin M. Berger purchased 60,000 shares of Proteostasis Therapeutics stock in a transaction dated Monday, December 18th. The stock was acquired at an average cost of $5.00 per share, with a total value of $300,000.00. Following the completion of the transaction, the director now directly owns 266,162 shares of the company’s stock, valued at $1,330,810. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Meenu Chhabra purchased 40,000 shares of Proteostasis Therapeutics stock in a transaction dated Monday, December 18th. The stock was bought at an average cost of $5.00 per share, with a total value of $200,000.00. Following the completion of the transaction, the insider now directly owns 50,218 shares of the company’s stock, valued at $251,090. The disclosure for this purchase can be found here. Insiders bought 2,100,000 shares of company stock valued at $10,500,000 over the last three months. 17.40% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Jennison Associates LLC raised its position in Proteostasis Therapeutics by 53.5% during the fourth quarter. Jennison Associates LLC now owns 3,178,432 shares of the company’s stock valued at $18,530,000 after acquiring an additional 1,107,496 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Proteostasis Therapeutics by 425.4% in the third quarter. JPMorgan Chase & Co. now owns 1,124,602 shares of the company’s stock valued at $2,361,000 after purchasing an additional 910,550 shares during the period. Monashee Investment Management LLC bought a new position in shares of Proteostasis Therapeutics in the fourth quarter valued at approximately $2,186,000. FMR LLC raised its position in shares of Proteostasis Therapeutics by 2.3% in the second quarter. FMR LLC now owns 2,944,915 shares of the company’s stock valued at $13,782,000 after purchasing an additional 66,111 shares during the period. Finally, Sabby Management LLC raised its position in shares of Proteostasis Therapeutics by 109.6% in the second quarter. Sabby Management LLC now owns 125,151 shares of the company’s stock valued at $586,000 after purchasing an additional 65,451 shares during the period. 55.15% of the stock is owned by institutional investors and hedge funds.

Proteostasis Therapeutics (NASDAQ:PTI) opened at $2.74 on Monday. Proteostasis Therapeutics has a fifty-two week low of $1.41 and a fifty-two week high of $16.67. The company has a market cap of $90.73, a PE ratio of -1.23 and a beta of 6.35.

COPYRIGHT VIOLATION NOTICE: “-$0.67 EPS Expected for Proteostasis Therapeutics Inc (PTI) This Quarter” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/12/0-67-eps-expected-for-proteostasis-therapeutics-inc-pti-this-quarter.html.

Proteostasis Therapeutics Company Profile

Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.

Get a free copy of the Zacks research report on Proteostasis Therapeutics (PTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply